Valeant Pharma (VRX) Names New Chief Quality Officer
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that Louis W. Yu, Ph.D. has been appointed to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016.
Dr. Yu will report to Joseph C. Papa, Chairman and CEO of Valeant. As a new member of Valeant's Executive Committee, Dr. Yu will oversee all aspects of quality and regulatory compliance for all of Valeant's global businesses and operating sites.
Dr. Yu joins Valeant with more than 30 years of leadership experience in the Quality and R&D functions of generic and branded pharmaceutical companies. He was Executive Vice President, Global Quality & Compliance at The Perrigo Company from November 2006 to January 2016, where he was responsible for strategic leadership and regulatory compliance as well as the global patient safety/medical affairs departments. He also served between May and September 2016 as the Senior Vice President, Global Quality and Compliance at AMRI, a contract development and manufacturing organization (CDMO) company.
"Delivering quality products leads to quality health outcomes, and that is what we are focused on at Valeant," said Joseph C. Papa, chief executive officer of Valeant. "Dr. Louis Yu is a great addition to our organization, and we are delighted to bring him into the company in the important new role of Chief Quality Officer. Dr. Yu's deep quality leadership experience at a number of branded and generic pharmaceutical companies gives him a deep understanding of what our customers and regulators need, and I look forward to working closely with him."
Dr. Yu said, "I appreciate the opportunity to lead Valeant's global quality function and am eager to help the company implement sustainable quality and compliance programs that will further strengthen its businesses."
Biography of Louis W. Yu, Ph. D.
Dr. Louis W. Yu is Chief Quality Officer, Global Quality of Valeant Pharmaceuticals, Inc.
Dr. Yu joined Valeant from AMRI where he was Senior Vice President, Global Quality and Compliance. From November 2006 to January 2016, he served as Executive Vice President, Global Quality and Compliance at The Perrigo Company, where he was responsible for strategic leadership and regulatory compliance as well as the global patient safety/medical affairs departments. Previously, he served as the highest quality officer for CV Therapeutics, Forest Laboratories and Solvay Pharmaceuticals USA. Earlier in his career, he served in the Quality and R&D organizations for over 16 years at various Johnson & Johnson companies in positions of increasing responsibility. He has been an adjunct professor at the School of Pharmacy, the University of Wisconsin, and currently is an adjunct faculty at the Purdue Polytechnic Institute in West Lafayette. Dr. Yu earned a B.S. in chemistry from the University of Wisconsin, and a M.S. and Ph.D. in analytical chemistry from Rutgers University.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CSS Industries (CSS) Names John Roselli as CFO
- Allergan (AGN) Announces FDA Approval Of RHOFADE Cream to Treat Redness Associated with Rosacea
- Western Union (WU) Announces Agreements to Resolve U.S. Investigations
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments, Short Sales
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!